Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 6 | BMC Complementary and Alternative Medicine

Figure 6

From: Ruscogenin ameliorates diabetic nephropathy by its anti-inflammatory and anti-fibrotic effects in streptozotocin-induced diabetic rat

Figure 6

Effects of treatments on NF-κB activity (A) and phosphorylated NF-κB (B) in renal tissues of rats. STZ-diabetic rats treated for eight weeks with ruscogenin (RUS) or rosiglitazone (Rosi). STZ-diabetic rats were dosed by oral gavage once daily for eight weeks with 3 mg/kg RUS (STZ + RUS) or 5 mg/kg RGZ (STZ + Rosi). Normal (normal + Veh) or STZ-diabetic rats receiving vehicle treatment (STZ + Veh) were administered the same volume of vehicle (Veh) used to prepare test medications. The mean density values of p-NF-κB were expressed as ratios relative to that of NF-κB. The level of lamin A was estimated for equal loading of nuclear sample. Values (mean ± SD) were obtained for each group of 5 animals. aP < 0.05 and bP < 0.01 compared with vehicle-treated normal rats (normal + Veh), respectively. cP < 0.05 and dP < 0.01 compared to vehicle-treated STZ-diabetic rats (STZ + Veh), respectively.

Back to article page